Hantavirus Outbreak Triggers Surge in Pharma Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Source: CNBC
- Pharma Stock Surge: Following the WHO's May 2 warning about the hantavirus outbreak, Moderna's stock rose 7% in premarket trading, indicating market confidence in its ability to address emerging infectious diseases.
- Research Collaboration: Moderna is conducting preclinical research on hantaviruses in collaboration with the US Army Medical Research Institute, although Evercore ISI believes this will not lead to significant revenue opportunities, it highlights the agility of its mRNA platform.
- Other Companies' Performance: Inovio Pharmaceuticals jumped 11% in early trading, while Novavax rose 5%, reflecting positive market sentiment towards vaccine development firms, despite limited overall market opportunities.
- Epidemic Control Status: President Trump stated that the outbreak on the cruise ship is under control, with the WHO reporting 8 confirmed cases and 3 deaths, assessing the public health risk as low, indicating the situation is manageable.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 70.030
Low
17.00
Averages
32.47
High
63.00
Current: 70.030
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna's Stock Surges Nearly 150% Amid Regulatory Progress
- Vaccine Regulatory Progress: On June 18, Moderna revealed that its mRNA flu vaccine, mRNA-1010, received unanimous support from an FDA advisory committee, indicating that the benefits outweigh the risks for patients aged 50 and over, with potential FDA approval by August 5, which could significantly enhance the company's competitive position in the flu vaccine market.
- Sentiment Boost: The recent investor day included a surprise announcement regarding the development of an in vivo CAR-T candidate, which, if successful, could diversify Moderna's product line into respiratory, oncology, and rare disease treatments, thereby enhancing future revenue potential.
- Valuation Risks: Despite the bullish sentiment, Moderna's market cap has reached $26.7 billion while remaining unprofitable, indicating that this valuation is heavily reliant on the future potential of its non-COVID-19 products, with the total addressable market for flu vaccines estimated at only $9.5 billion, necessitating a dominant market share for profitability.
- Increased Financing Risks: As Moderna continues to burn through cash to fund its post-COVID-19 recovery, the risk of a dilutive equity offering rises, and while there is optimism about its long-term rebound potential, investors may need to exercise caution until the recent hype subsides.
See More
Moderna's mRNA Flu Vaccine Gains FDA Support
- Vaccine Development Progress: On June 18, Moderna announced that its mRNA flu vaccine, mRNA-1010, received unanimous support from an FDA advisory committee, indicating significant market potential among patients aged 50 and over, with FDA approval expected by August 5, potentially opening new revenue streams for the company.
- Market Rebound Dynamics: Despite Moderna's stock price surging nearly 150% over the past year to a market cap of $26.7 billion, analysts caution that much of this recovery potential is already priced in, and future profitability will depend on capturing market share in non-COVID-19 products.
- Diversification Strategy: The company unexpectedly announced plans to develop an in vivo CAR-T candidate during its recent investor day, which, if successful, could help Moderna diversify into respiratory, oncology, and rare disease treatments, enhancing its competitive position in the market.
- Financial Risk Warning: While market sentiment remains bullish, Moderna faces risks related to cash burn and may need to pursue dilutive equity offerings to fund its post-COVID-19 recovery, prompting investors to carefully consider their timing for entry.
See More
Nike Shares Plummet, Underperforming in Dow Industrials
- Nike Stock Decline: Nike shares have fallen nearly 20% over the past three months and are down 48% from the August 2025 high, making it the worst performer in the Dow Industrials, only better than Chevron, indicating significant weakness in its market position.
- Year-to-Date Performance: Year-to-date, Nike's stock is down about 35%, and no other Dow constituent has performed worse in the past 12 months, highlighting the challenges it faces in the highly competitive sports apparel market.
- Constellation Brands Struggles: Constellation Brands, the maker of Corona and Modelo beers, has seen its stock drop nearly 8% in the last three months and is down 21% from its July 2025 high, reflecting pressure in its market segment.
- Healthcare Sector Strength: The healthcare sector has risen nearly 8% in the past month, with Moderna's stock surging 47%, indicating a strong recovery in the sector and investor confidence in its growth potential.
See More
Moderna Outlines Future Growth Plans at Science Day
- Vaccine Development Focus: At Science Day, Moderna outlined its growth plans across infectious disease vaccines, Intismeran, and rare disease therapeutics, with CEO Bancel stating that Horizon 2 programs are already in the clinic and Horizon 3 programs are expected to enter human testing by the end of 2027, laying a solid foundation for future product line expansion.
- mRED Strategy Implementation: Moderna's mRED strategy aims to quickly test early 'sentinel' programs, promptly halt ineffective drugs, and accelerate promising ones, ensuring swift decision-making during the high-risk clinical development phase, thereby enhancing R&D efficiency and mitigating risks.
- Significant Cancer Pipeline Progress: Moderna highlighted its mRNA projects targeting various cancers, including mRNA-4106 and mRNA-4200, particularly mRNA-4194 as its first cancer prevention program aimed at training the immune system to recognize cancer-linked peptides, showcasing strong market potential for early disease targeting.
- AI Technology Enhancing R&D: Moderna introduced its Scientific Intelligence Engine, Lucy, emphasizing the scientific advantage of rapid learning, while its flu vaccine candidate mRNA-1010 received a 9-0 vote of support from the FDA advisory committee, expected to provide an important new option for seasonal flu prevention, further strengthening the company's competitive position.
See More
Moderna Outlines Future Growth Plans at Science Day
- Future Growth Strategy: At Science Day, Moderna outlined its growth plans across infectious disease vaccines, Intismeran, and rare disease therapeutics, with CEO Stephane Bancel stating that Horizon 2 programs are already in the clinic and Horizon 3 programs are expected to enter human testing by the end of 2027, showcasing the company's forward-looking approach in vaccine development.
- Cancer Pipeline Progress: Moderna highlighted mRNA-4106 and mRNA-4200 for advanced solid tumors, along with mRNA-4194 targeting Lynch syndrome, which is the company's first cancer prevention study aimed at training the immune system to recognize 194 cancer-linked frameshift peptides, indicating potential for early intervention.
- Multiple Sclerosis Research: The mRNA-1195 program targets the Epstein-Barr virus, closely linked to multiple sclerosis, with the Phase 2 study fully enrolling its first group of patients, and an independent safety board recommending moving to dose escalation, suggesting initial safety and efficacy have been recognized.
- Flu Vaccine Regulatory Progress: Moderna's flu vaccine candidate mRNA-1010 received a 9-0 vote of support from the FDA advisory committee, indicating that its benefits outweigh risks for adults aged 50 and older, which is expected to provide an important new option for seasonal flu prevention and further solidify the company's position in the vaccine market.
See More
Biotech Stocks Hit 52-Week Highs Amid Speculation and Trials
- Sellas Life Sciences Surge: Sellas Life Sciences' stock soared 17% to a 52-week high of $12.43 as record short interest and acquisition speculation fueled investor optimism, particularly ahead of a key update from its Phase 3 AML trial.
- Moderna's Pipeline Advances: Moderna's stock rose 12% to $69.29 following its Science Day presentation, where it showcased advancements in cancer, autoimmune, and rare disease therapies, emphasizing its strategic use of AI and automation in drug discovery.
- AbCellera's Major Partnership: AbCellera Biologics' stock climbed over 10% to a two-year high of $7.40 due to its research collaboration with Jazz Pharmaceuticals, which includes $56 million in upfront funding, indicating strong market confidence in their T-cell engager antibody programs.
- Investor Sentiment Optimism: The closing highs for Sellas Life Sciences, Moderna, and AbCellera Biologics on Friday reflect robust investor confidence in biotech firms, particularly those with identifiable near-term clinical events and business catalysts.
See More
Moderna's Stock Surges Nearly 150% Amid Regulatory Progress
- Vaccine Regulatory Progress: On June 18, Moderna revealed that its mRNA flu vaccine, mRNA-1010, received unanimous support from an FDA advisory committee, indicating that the benefits outweigh the risks for patients aged 50 and over, with potential FDA approval by August 5, which could significantly enhance the company's competitive position in the flu vaccine market.
- Sentiment Boost: The recent investor day included a surprise announcement regarding the development of an in vivo CAR-T candidate, which, if successful, could diversify Moderna's product line into respiratory, oncology, and rare disease treatments, thereby enhancing future revenue potential.
- Valuation Risks: Despite the bullish sentiment, Moderna's market cap has reached $26.7 billion while remaining unprofitable, indicating that this valuation is heavily reliant on the future potential of its non-COVID-19 products, with the total addressable market for flu vaccines estimated at only $9.5 billion, necessitating a dominant market share for profitability.
- Increased Financing Risks: As Moderna continues to burn through cash to fund its post-COVID-19 recovery, the risk of a dilutive equity offering rises, and while there is optimism about its long-term rebound potential, investors may need to exercise caution until the recent hype subsides.
See More
Moderna's mRNA Flu Vaccine Gains FDA Support
- Vaccine Development Progress: On June 18, Moderna announced that its mRNA flu vaccine, mRNA-1010, received unanimous support from an FDA advisory committee, indicating significant market potential among patients aged 50 and over, with FDA approval expected by August 5, potentially opening new revenue streams for the company.
- Market Rebound Dynamics: Despite Moderna's stock price surging nearly 150% over the past year to a market cap of $26.7 billion, analysts caution that much of this recovery potential is already priced in, and future profitability will depend on capturing market share in non-COVID-19 products.
- Diversification Strategy: The company unexpectedly announced plans to develop an in vivo CAR-T candidate during its recent investor day, which, if successful, could help Moderna diversify into respiratory, oncology, and rare disease treatments, enhancing its competitive position in the market.
- Financial Risk Warning: While market sentiment remains bullish, Moderna faces risks related to cash burn and may need to pursue dilutive equity offerings to fund its post-COVID-19 recovery, prompting investors to carefully consider their timing for entry.
See More
Nike Shares Plummet, Underperforming in Dow Industrials
- Nike Stock Decline: Nike shares have fallen nearly 20% over the past three months and are down 48% from the August 2025 high, making it the worst performer in the Dow Industrials, only better than Chevron, indicating significant weakness in its market position.
- Year-to-Date Performance: Year-to-date, Nike's stock is down about 35%, and no other Dow constituent has performed worse in the past 12 months, highlighting the challenges it faces in the highly competitive sports apparel market.
- Constellation Brands Struggles: Constellation Brands, the maker of Corona and Modelo beers, has seen its stock drop nearly 8% in the last three months and is down 21% from its July 2025 high, reflecting pressure in its market segment.
- Healthcare Sector Strength: The healthcare sector has risen nearly 8% in the past month, with Moderna's stock surging 47%, indicating a strong recovery in the sector and investor confidence in its growth potential.
See More
Moderna Outlines Future Growth Plans at Science Day
- Vaccine Development Focus: At Science Day, Moderna outlined its growth plans across infectious disease vaccines, Intismeran, and rare disease therapeutics, with CEO Bancel stating that Horizon 2 programs are already in the clinic and Horizon 3 programs are expected to enter human testing by the end of 2027, laying a solid foundation for future product line expansion.
- mRED Strategy Implementation: Moderna's mRED strategy aims to quickly test early 'sentinel' programs, promptly halt ineffective drugs, and accelerate promising ones, ensuring swift decision-making during the high-risk clinical development phase, thereby enhancing R&D efficiency and mitigating risks.
- Significant Cancer Pipeline Progress: Moderna highlighted its mRNA projects targeting various cancers, including mRNA-4106 and mRNA-4200, particularly mRNA-4194 as its first cancer prevention program aimed at training the immune system to recognize cancer-linked peptides, showcasing strong market potential for early disease targeting.
- AI Technology Enhancing R&D: Moderna introduced its Scientific Intelligence Engine, Lucy, emphasizing the scientific advantage of rapid learning, while its flu vaccine candidate mRNA-1010 received a 9-0 vote of support from the FDA advisory committee, expected to provide an important new option for seasonal flu prevention, further strengthening the company's competitive position.
See More
Moderna Outlines Future Growth Plans at Science Day
- Future Growth Strategy: At Science Day, Moderna outlined its growth plans across infectious disease vaccines, Intismeran, and rare disease therapeutics, with CEO Stephane Bancel stating that Horizon 2 programs are already in the clinic and Horizon 3 programs are expected to enter human testing by the end of 2027, showcasing the company's forward-looking approach in vaccine development.
- Cancer Pipeline Progress: Moderna highlighted mRNA-4106 and mRNA-4200 for advanced solid tumors, along with mRNA-4194 targeting Lynch syndrome, which is the company's first cancer prevention study aimed at training the immune system to recognize 194 cancer-linked frameshift peptides, indicating potential for early intervention.
- Multiple Sclerosis Research: The mRNA-1195 program targets the Epstein-Barr virus, closely linked to multiple sclerosis, with the Phase 2 study fully enrolling its first group of patients, and an independent safety board recommending moving to dose escalation, suggesting initial safety and efficacy have been recognized.
- Flu Vaccine Regulatory Progress: Moderna's flu vaccine candidate mRNA-1010 received a 9-0 vote of support from the FDA advisory committee, indicating that its benefits outweigh risks for adults aged 50 and older, which is expected to provide an important new option for seasonal flu prevention and further solidify the company's position in the vaccine market.
See More
Biotech Stocks Hit 52-Week Highs Amid Speculation and Trials
- Sellas Life Sciences Surge: Sellas Life Sciences' stock soared 17% to a 52-week high of $12.43 as record short interest and acquisition speculation fueled investor optimism, particularly ahead of a key update from its Phase 3 AML trial.
- Moderna's Pipeline Advances: Moderna's stock rose 12% to $69.29 following its Science Day presentation, where it showcased advancements in cancer, autoimmune, and rare disease therapies, emphasizing its strategic use of AI and automation in drug discovery.
- AbCellera's Major Partnership: AbCellera Biologics' stock climbed over 10% to a two-year high of $7.40 due to its research collaboration with Jazz Pharmaceuticals, which includes $56 million in upfront funding, indicating strong market confidence in their T-cell engager antibody programs.
- Investor Sentiment Optimism: The closing highs for Sellas Life Sciences, Moderna, and AbCellera Biologics on Friday reflect robust investor confidence in biotech firms, particularly those with identifiable near-term clinical events and business catalysts.
See More
